Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan 13:10:e64281.
doi: 10.7554/eLife.64281.

High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination

Adam S Dingens  1 , Payal Pratap  2 , Keara Malone  1 , Sarah K Hilton  1 , Thomas Ketas  3 , Christopher A Cottrell  2 , Julie Overbaugh  4 , John P Moore  3 , P J Klasse  3 , Andrew B Ward  2 , Jesse D Bloom  1   5
Affiliations

High-resolution mapping of the neutralizing and binding specificities of polyclonal sera post-HIV Env trimer vaccination

Adam S Dingens et al. Elife. .

Abstract

Mapping polyclonal serum responses is critical to rational vaccine design. However, most high-resolution mapping approaches involve isolating and characterizing individual antibodies, which incompletely defines the polyclonal response. Here we use two complementary approaches to directly map the specificities of the neutralizing and binding antibodies of polyclonal anti-HIV-1 sera from rabbits immunized with BG505 Env SOSIP trimers. We used mutational antigenic profiling to determine how all mutations in Env affected viral neutralization and electron microscopy polyclonal epitope mapping (EMPEM) to directly visualize serum Fabs bound to Env trimers. The dominant neutralizing specificities were generally only a subset of the more diverse binding specificities. Additional differences between binding and neutralization reflected antigenicity differences between virus and soluble Env trimer. Furthermore, we refined residue-level epitope specificity directly from sera, revealing subtle differences across sera. Together, mutational antigenic profiling and EMPEM yield a holistic view of the binding and neutralizing specificity of polyclonal sera.

Keywords: Env trimer immunization; HIV; electron microscopy polyclonal epitope mapping; immunology; infectious disease; inflammation; microbiology; mutational antigenic profiling; polyclonal sera; virus.

Plain language summary

Vaccines work by stimulating the immune system to produce proteins called antibodies. These antibodies bind to the virus targeted by the vaccine and block the virus from infecting cells. It has been difficult to develop a vaccine for HIV because frequent mutations allow it to evade antibodies. Understanding exactly how these proteins bind to HIV and how various mutations enable the virus to escape them is crucial to designing a successful HIV vaccine. Over the last decade, scientists have developed new techniques for studying individual antibodies and how they bind to viruses. Now, they are using these insights to design vaccines. Most vaccines result in the production of many antibodies that bind to different parts of the virus, making it harder for a virus to escape. But studying many antibodies with different targets on the virus simultaneously remains challenging. By combining two-cutting edge approaches, Dingens et al. catalogued the many antibodies that rabbits produce in response to an experimental vaccine for HIV. In the experiments, they mapped how two types of rabbit antibodies target the virus: those that could bind to the virus, and those that could both bind and neutralize the virus (i.e., block it from infecting cells). The experiments showed that small differences between the HIV virus and the vaccine explained why some rabbit antibodies created in response to the vaccine could bind but not neutralize the virus. Moreover, the ability to stop HIV from infecting the cells appeared to be reserved to antibodies that could bind to several different locations at the virus. Dingens et al. further documented all the virus mutations that would allow it to evade neutralizing antibodies. The techniques used in the experiments may help scientists identify the best sites on the HIV virus to target with vaccines and to better understand the binding and neutralizing activity of antibodies. The results of the experiments may also help to redesign the experimental HIV vaccine – which is currently being tested in humans – to be even more effective.

PubMed Disclaimer

Conflict of interest statement

AD, PP, KM, SH, TK, CC, JM, PK, AW, JB No competing interests declared, JO Reviewing editor, eLife

Figures

Figure 1.
Figure 1.. Overview of sera and epitope mapping approaches.
(A) Preliminary point-mutant mapping of the BG505-trimer-vaccinated sera panel. The sera dilution that inhibits 50% of virus entry (ID50), maximum neutralization percentage plateau (MNP), and fold change in ID50 values of wild type relative to mutant pseudoviruses (WT/Mut ID50) are shown for the parental BG505.T332N and pseudoviruses bearing insertion (V1 epitope) and glycan knock in mutation(s) (GH and C3/V5 epitopes). The weeks (Wk) post-initial vaccination of the serum sample is specified in each sera’s name; sera are subsequently referred to by only their four-digit ID number. (B) Experimental schematic of mutational antigenic profiling. (C) Experimental schematic of EMPEM.
Figure 1—figure supplement 1.
Figure 1—figure supplement 1.. Experimental details for all mutational antigenic profiling experiments.
The Library is the stock of independently passaged mutant virus library used in each experiment. The percentage of the mutant virus library that successfully entered cells after serum selection (% Infectivity) was measured using qPCR standard curves. The correlation matrix shows the Pearson’s r correlation coefficient of the positive site differential selection values between replicates.
Figure 2.
Figure 2.. Serum neutralization-escape mutations mapped by mutational antigenic profiling.
(A) Line plots showing the positive site differential selection for each serum across the Env ectodomain. Differential selection is a measure of the enrichment of mutations in the sera-selected conditions relative to a no-sera control (see Materials and methods for details). (B) Differential selection for each mutation at key sites (indicated with orange underlines in (A)). The height of each letter is proportional to the differential selection for that amino-acid mutation. The GH epitope is colored green, and the C3/V5 epitope is colored blue. Mutations tested during preliminary point-mutant mapping are colored black (Figure 1A; all mutations that add a tested glycan are indicated). For both (A) and (B), the y-axis is scaled to the maximal effect size site for each sera; sera without a single dominant region of escape (2243 and 2214) are plotted such that 90% of the site-level signal is at <20% of the y-axis maximum. (C) The positive site differential selection is mapped onto the BG505 trimer (PDB: 5FYL). The color scheme is right censored at 15 to visualize subdominant responses; for samples with a maximum selection less than 15, the maximum value is mapped to most red color. An interactive version of these visualizations is at https://jbloomlab.github.io/Vacc_Rabbit_Sera_MAP/. Raw numerical values and logo plots for the entire Env ectodomain are in Figure 2—source data 1.
Figure 2—figure supplement 1.
Figure 2—figure supplement 1.. Mutational antigenic profiling data plotted for each individual replicates of pre- and post-immunization sera from rabbit 5724.
Data are plotted as in Figure 2A,B for each, but with mutations colored according to their biochemical property rather than epitope.
Figure 2—figure supplement 2.
Figure 2—figure supplement 2.. Mutational antigenic profiling data plotted for each individual replicates of pre- and post-immunization sera from rabbit 2214.
Data are plotted as in Figure 2A,B for each, but with mutations colored according to their biochemical property rather than epitope.
Figure 2—figure supplement 3.
Figure 2—figure supplement 3.. Mutational antigenic profiling data plotted for each individual replicates of pre- and post-immunization sera from rabbit 5727.
Data are plotted as in Figure 2A,B for each, but with mutations colored according to their biochemical property rather than epitope.
Figure 2—figure supplement 4.
Figure 2—figure supplement 4.. Mutational antigenic profiling data plotted for each individual replicates of pre- and post-immunization sera from rabbit 2124.
Data are plotted as in Figure 2A,B for each, but with mutations colored according to their biochemical property rather than epitope.
Figure 2—figure supplement 5.
Figure 2—figure supplement 5.. Mutational antigenic profiling data plotted for each individual replicates of pre- and post-immunization sera from rabbit 2423.
Data are plotted as in Figure 2A,B for each, but with mutations colored according to their biochemical property rather than epitope.
Figure 2—figure supplement 6.
Figure 2—figure supplement 6.. Mutational antigenic profiling data plotted for each individual replicates of pre- and post-immunization sera from rabbit 2425.
Data are plotted as in Figure 2A,B for each, but with mutations colored according to their biochemical property rather than epitope.
Figure 2—figure supplement 7.
Figure 2—figure supplement 7.. Validation of mutational antigenic profiling in neutralization assays.
(A) The fold enrichment in mutational antigenic profiling and the fold change in ID50 relative to wild type and maximum neutralization plateau (MNP) from TZM-bl neutralization assays for the maximal effect mutant at the maximal effect site. The color scheme is as in Figure 1A. (B) Correlation between fold change ID50 relative to wild type in TZM-bl neutralization assays and the fold enrichment in mutational antigenic profiling. The Pearson’s correlation coefficient is shown.
Figure 3.
Figure 3.. Comparing the binding and neutralization specificities of the sera.
(A) Refined 3D reconstructions from negative stain EMPEM. Specificities are mapped onto the Env trimer structure, with epitopes colored as in (C). (B) Mutational antigenic profiling data mapped onto the BG505 SOSIP Env structure, as in Figure 2C, represented here to contrast with EMPEM. (C) Summary data from (A) and (B), as well as validation TZM-bl neutralization assay point-mutant mapping of single and double epitope knock out mutations (see Figure 3—figure supplement 1 for details). A checkmark (EMPEM and MAP) indicates a response was detected to that epitope, and TZM-bl responses were summarized as ‘Dominant’, ‘Subdominant’, or undetected (left blank) based on data in Figure 3—figure supplement 1. We did not perform neutralization assay validation at epitopes where the discrepancies between the EMPEM and mutational antigenic profiling are easily explained by antigenicity differences between soluble trimer and virus (N611, base, and gp120 interface; labeled as ‘Not tested’).
Figure 3—figure supplement 1.
Figure 3—figure supplement 1.. Effect of mutations that disrupt the C3/V5, glycan hole, and V1 epitopes alone and in combination with other epitope knockouts.
Mutations are colored according to epitope, as in Figure 3. The standard deviation of replicate measures is shown in parentheses. Mutants labeled with an (*) are from the preliminary point-mutant mapping in Figure 1A; these experiments were performed in a different lab than the remainder of TZM-bl point-mutant mapping. While fold change in ID50 was always compared to a wild-type virus ran in parallel in independent labs, results across labs should only be interpreted generally (as presented in Figure 3C).
Figure 4.
Figure 4.. C3/V5 residue-level epitope specificity.
(A) Differential selection is plotted in logo plots for the C3/V5 epitope, as in Figure 1B. Mutations validated in TZM-bl neutralization assays (C) are colored black. The y-axis is scaled to the largest effect size site. (B) The positive site differential selection is mapped onto the BG505 trimer (PDB: 5FYL), colored as in Figure 1C. Sites shown in (A) are shown with spheres in (B). These data can be explored interactively using dms-view at https://jbloomlab.github.io/Vacc_Rabbit_Sera_MAP/. (C) The fold change in ID50 relative to wild type and the maximum neutralization plateau (MNP) for each mutant validated in a pseudovirus TZM-bl neutralization assay. The table color scheme is as in Figure 1A, and the standard deviation of replicate measures are shown in parentheses. See Figure 4—figure supplement 1 for the single sera with relatively less targeting of this epitope.
Figure 4—figure supplement 1.
Figure 4—figure supplement 1.. A, B, and C as in Figure 4, but for the single sera with limited targeting of the C3/V5 epitope.
Figure 5.
Figure 5.. Glycan hole epitope specificity.
(A) Differential selection is plotted in logo plots for the glycan hole epitope, as in Figure 1B. Mutations validated in TZM-bl neutralization assays (C) are colored black. The y-axis is scaled to the largest effect size site, which is oftentimes not in this GH view. (B) The positive site differential selection is mapped onto the BG505 trimer (PDB: 5FYL), with a single monomer shown and colored as in Figure 1C. Sites shown in (A) are shown with spheres in (B). These data can be explored interactively using dms-view at https://jbloomlab.github.io/Vacc_Rabbit_Sera_MAP/. (C) The fold change in ID50 relative to wild type and the maximum neutralization plateau (MNP) for each mutant validated in a pseudovirus TZM-bl neutralization assay. The table color scheme is as in Figure 1A, and the standard deviation of replicate measures are shown in parentheses. The table color scheme is as in Figure 1A. See Figure 5—figure supplement 1 for the three sera with limited targeting of this epitope.
Figure 5—figure supplement 1.
Figure 5—figure supplement 1.. (A), (B), and (C) as in Figure 5, but for the three sera with limited targeting of the glycan hole epitope.
See this image and copyright information in PMC

References

    1. Ackerman ME, Barouch DH, Alter G. Systems serology for evaluation of HIV vaccine trials. Immunological Reviews. 2017;275:262–270. doi: 10.1111/imr.12503. - DOI - PMC - PubMed
    1. Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, Radakovich NA, Anasti K, Armand L, Parks R, Sutherland L, Scearce R, Joyce MG, Pancera M, Druz A, Georgiev IS, Von Holle T, Eaton A, Fox C, Reed SG, Louder M, Bailer RT, Morris L, Abdool-Karim SS, Cohen M, Liao HX, Montefiori DC, Park PK, Fernández-Tejada A, Wiehe K, Santra S, Kepler TB, Saunders KO, Sodroski J, Kwong PD, Mascola JR, Bonsignori M, Moody MA, Danishefsky S, Haynes BF. Mimicry of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. Science Translational Medicine. 2017;9:eaai7521. doi: 10.1126/scitranslmed.aai7521. - DOI - PMC - PubMed
    1. Barnes CO, West AP, Huey-Tubman KE, Hoffmann MAG, Sharaf NG, Hoffman PR, Koranda N, Gristick HB, Gaebler C, Muecksch F, Lorenzi JCC, Finkin S, Hägglöf T, Hurley A, Millard KG, Weisblum Y, Schmidt F, Hatziioannou T, Bieniasz PD, Caskey M, Robbiani DF, Nussenzweig MC, Bjorkman PJ. Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies. Cell. 2020;182:828–842. doi: 10.1016/j.cell.2020.06.025. - DOI - PMC - PubMed
    1. Bianchi M, Turner HL, Nogal B, Cottrell CA, Oyen D, Pauthner M, Bastidas R, Nedellec R, McCoy LE, Wilson IA, Burton DR, Ward AB, Hangartner L. Electron-Microscopy-Based epitope mapping defines specificities of polyclonal antibodies elicited during HIV-1 BG505 envelope trimer immunization. Immunity. 2018;49:288–300. doi: 10.1016/j.immuni.2018.07.009. - DOI - PMC - PubMed
    1. Bloom JD. Software for the analysis and visualization of deep mutational scanning data. BMC Bioinformatics. 2015;16:1–13. doi: 10.1186/s12859-015-0590-4. - DOI - PMC - PubMed

Publication types

Substances